115 related articles for article (PubMed ID: 30680449)
41. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
[TBL] [Abstract][Full Text] [Related]
42. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
43. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
44. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
45. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
[TBL] [Abstract][Full Text] [Related]
46. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer.
Delea TE; Vera-Llonch M; Edelsberg JS; McGarry L; Anton S; Ulcickas-Yood M; Oster G
Value Health; 2002; 5(1):35-43. PubMed ID: 11873382
[TBL] [Abstract][Full Text] [Related]
47. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
48. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR
J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472
[TBL] [Abstract][Full Text] [Related]
49. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
Semira C; Wong HL; Field K; Lee M; Lee B; Nott L; Shapiro J; Wong R; Tie J; Tran B; Richardson G; Zimet A; Lipton L; Tamjid B; Burge M; Ma B; Johns J; Harold M; Gibbs P
Intern Med J; 2019 Apr; 49(4):446-454. PubMed ID: 30230679
[TBL] [Abstract][Full Text] [Related]
51. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
52. Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Kabbinavar FF; Ellis LM
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S69-73. PubMed ID: 15479482
[TBL] [Abstract][Full Text] [Related]
53. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Köhne CH; Cunningham D; Di Costanzo F; Glimelius B; Blijham G; Aranda E; Scheithauer W; Rougier P; Palmer M; Wils J; Baron B; Pignatti F; Schöffski P; Micheel S; Hecker H
Ann Oncol; 2002 Feb; 13(2):308-17. PubMed ID: 11886010
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
55. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
Zhu LM; Zhao YZ; Ju HX; Liu LY; Chen L; Liu BX; Xu Q; Luo C; Ying JE; Yang YS; Zhong HJ
Asian Pac J Cancer Prev; 2014; 15(16):6559-64. PubMed ID: 25169487
[TBL] [Abstract][Full Text] [Related]
57. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
Ward P; Hecht JR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Naeim A
J Geriatr Oncol; 2014 Oct; 5(4):368-75. PubMed ID: 25002322
[TBL] [Abstract][Full Text] [Related]
58. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
[TBL] [Abstract][Full Text] [Related]
59. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
60. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer.
Cen P; Liu C; Du XL
Ann Oncol; 2012 Jun; 23(6):1503-11. PubMed ID: 22021820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
